Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge
Authors
Keywords
-
Journal
Future Oncology
Volume 12, Issue 11, Pages 1413-1428
Publisher
Future Medicine Ltd
Online
2016-03-24
DOI
10.2217/fon-2015-0025
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
- (2016) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer
- (2016) Edith A. Perez et al. JAMA Oncology
- Clinical implications of the intrinsic molecular subtypes of breast cancer
- (2015) Aleix Prat et al. BREAST
- PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
- (2015) H. M. Stern et al. CLINICAL CANCER RESEARCH
- Immune Signature to Predict Trastuzumab Benefit: Potential and Pitfalls
- (2015) Patrick G. Gavin et al. JOURNAL OF CLINICAL ONCOLOGY
- Reply to P.G. Gavin et al
- (2015) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Intrinsic Subtypes,PIK3CAMutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial
- (2015) Katherine L. Pogue-Geile et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer
- (2015) Ian J. Majewski et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CAGenotype and Treatment Decisions in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2015) David W. Cescon et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial
- (2015) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring anERBB2S310F Mutation
- (2015) Saranya Chumsri et al. Journal of the National Comprehensive Cancer Network
- Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
- (2015) Sara A Hurvitz et al. LANCET ONCOLOGY
- Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer
- (2015) V. Guarneri et al. ONCOLOGIST
- Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration
- (2015) Tiziana Triulzi et al. Oncotarget
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
- (2014) S. Loi et al. ANNALS OF ONCOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
- (2014) L. Castagnoli et al. CANCER RESEARCH
- Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
- (2014) A. Prat et al. CLINICAL CANCER RESEARCH
- PIK3CAMutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer
- (2014) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- (2014) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
- (2014) Aleix Prat et al. JNCI-Journal of the National Cancer Institute
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- The immune system and response to HER2-targeted treatment in breast cancer
- (2014) Giampaolo Bianchini et al. LANCET ONCOLOGY
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- (2014) Gunter von Minckwitz et al. LANCET ONCOLOGY
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Fabrice André et al. LANCET ONCOLOGY
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
- (2013) A. Schneeweiss et al. ANNALS OF ONCOLOGY
- Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
- (2013) Mario Giuliano et al. Breast Care
- Mammary Tumor Formation and Metastasis Evoked by a HER2 Splice Variant
- (2013) A. Alajati et al. CANCER RESEARCH
- Noncanonical roles of the immune system in eliciting oncogene addiction
- (2013) Stephanie C Casey et al. CURRENT OPINION IN IMMUNOLOGY
- Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial
- (2013) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31
- (2013) Katherine L. Pogue-Geile et al. JNCI-Journal of the National Cancer Institute
- 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
- (2013) Aron Goldhirsch et al. LANCET
- Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
- (2013) André Robidoux et al. LANCET ONCOLOGY
- 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
- (2013) Xavier Pivot et al. LANCET ONCOLOGY
- Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment
- (2013) Grit S. Herter-Sprie et al. Frontiers in Oncology
- Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells
- (2012) Chi Zhang et al. BREAST CANCER RESEARCH AND TREATMENT
- Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer
- (2012) G Minuti et al. BRITISH JOURNAL OF CANCER
- Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
- (2012) Valentina Guarneri et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Activity and resistance of trastuzumab according to different clinical settings
- (2011) Elda Tagliabue et al. CANCER TREATMENT REVIEWS
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
- (2011) Siyuan Zhang et al. NATURE MEDICINE
- Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients
- (2011) Maurizio Scaltriti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
- (2010) SaeGwang Park et al. CANCER CELL
- Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation
- (2010) Ke Liang et al. CANCER CELL
- CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation
- (2010) Kavya Rakhra et al. CANCER CELL
- Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin
- (2010) X. Huang et al. CANCER RESEARCH
- HER2 as a target for breast cancer therapy
- (2010) Elda Tagliabue et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2010) Luca Gianni et al. LANCET
- Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy
- (2009) G. Zhuang et al. CANCER RESEARCH
- Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2009) Neil L. Spector et al. JOURNAL OF CLINICAL ONCOLOGY
- Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents
- (2009) J. J.M. Boone et al. MOLECULAR CANCER THERAPEUTICS
- An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance
- (2009) D. Mitra et al. MOLECULAR CANCER THERAPEUTICS
- Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
- (2008) D. L. Shattuck et al. CANCER RESEARCH
- Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review
- (2008) Yolanda Madarnas et al. CANCER TREATMENT REVIEWS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search